Page 2 - Pathalys Pharma News Today

– Sebetralstat Phase 3 KONFIDENT and KVD824 Phase 2 KOMPLETE Clinical Trial Enrollment on Track –– Formal Notification Received of Sebetralstat EU Orphan Drug Status –CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused...

/PRNewswire/ -- Pathalys Pharma, Inc., a private, late-stage biopharma company committed to the development and commercialization of a range of best-in-class...

- Patrick A. Treanor Appointed Effective Immediately - - Dan Soland Resigns in Planned Transition - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused

/PRNewswire/ -- Pathalys Pharma, Inc., a private, late-stage biopharma company committed to the development and commercialization of a range of best-in-class...

/PRNewswire/ -- Pathalys Pharma, Inc., a private, late-stage biopharma company committed to the development and commercialization of a range of best-in-class...

Pathalys Pharma Announces Executive Team Appointments - read this article along with other careers information, tips and advice on BioSpace

Pathalys Pharma, a newly formed RTP biopharmaceutical company developing therapies for chronic kidney disease, has announced its executive leadership team, led by pharma veteran Neal Fowler.

/PRNewswire/ -- Pathalys Pharma, Inc., a private, late-stage biopharma company committed to the development and commercialization of a range of best-in-class...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

/PRNewswire/ -- Pathalys Pharma, Inc., a private, late-stage biopharma company committed to the development and commercialization of a range of best-in-class...